HBV BASAL CORE PROMOTER MUTATION

 This test detects mutations in the basal core promoter (BCP) region of the Hepatitis B virus (HBV). These mutations are known to influence viral replication, progression of liver disease, and the risk of developing hepatocellular carcinoma (liver cancer). The test is crucial for identifying patients with a more aggressive form of HBV or those who might not respond well to standard antiviral treatments. It provides guidance on disease monitoring and therapeutic strategies.

A blood sample is collected and processed using molecular diagnostic techniques such as polymerase chain reaction (PCR) and DNA sequencing. These methods allow for the precise identification of mutations in the BCP region of the HBV genome. The most common mutations evaluated include the A1762T and G1764A variants, which are strongly associated with increased disease severity.

Detection of BCP mutations suggests a higher risk of liver inflammation, fibrosis, or cancer, even if standard liver function tests appear normal. It may also correlate with lower levels of HBeAg (Hepatitis B e Antigen) in the blood despite active viral replication. This discordance can mislead clinicians unless molecular testing is done. As a result, patients with such mutations often require more rigorous follow-up and possibly more aggressive antiviral therapy.

 While not routinely done in all HBV-positive patients, it is particularly useful in those with abnormal disease patterns, unclear HBeAg status, or rising liver enzymes. It is also recommended for patients with a family history of liver cancer or those being evaluated for liver transplant.

There is no specific preparation required for this test. However, sharing your complete HBV treatment history and clinical background with your doctor ensures proper interpretation of the results in context.